All Molecular Biology articles
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
ArticleTurning GWAS signals into drug targets with scalable CRISPR
Genome-wide association studies have linked thousands of genetic variants to disease, yet most remain disconnected from drug-relevant biology. Neville Sanjana, Professor at New York University and Core Faculty Member at the New York Genome Center, explains how scalable CRISPR screens systematically link noncoding variants to causal genes and therapeutic targets.
-
NewsPERM1 protein linked to heart recovery in LVAD patients
A newly identified protein may explain why some failing hearts recover function following mechanical support while others do not.
-
NewsNew study indentifies Golgi apparatus proteins as cancer growth drivers
Researchers at the Harrington Discovery Institute have identified cellular mechanisms involving Golgi apparatus proteins that drive cancer progression by trafficking growth factor receptors to cell surfaces.
-
ArticleAACR 2026 part 1: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.
-
NewsMYC protein found to repair DNA in cancer cells
Oregon Health & Science University researchers have identified a non-canonical function of the MYC oncoprotein in DNA damage repair, revealing how tumour cells survive chemotherapy-induced stress.
-
NewsNew RNA sequencing method reveals molecular structures at single-molecule resolution
A*STAR scientists have developed sm-PORE-cupine, a nanopore-based sequencing method that maps individual RNA structures at single-molecule resolution.
-
NewsMolecular switch discovery could lead to new bone disease treatments
A molecular switch that activates an alternative energy-burning pathway in brown fat has been identified by McGill University researchers, offering potential new approaches to treating bone disease and metabolic disorders through the TNAP enzyme’s glycerol pocket.
-
NewsYAP1 protein found to drive chemotherapy resistance in small cell lung cancer after treatment
University of Texas MD Anderson Cancer Center researchers have discovered that YAP1 protein expression emerges after chemotherapy treatment in small cell lung cancer, enabling resistant cancer cells to survive and proliferate.
-
NewsProtein modifications control drug binding and efficacy in new study
New research reveals that subtle chemical changes to proteins after synthesis play a critical role in determining drug-protein interactions.
-
NewsAI tool reveals DNA exists in partially open states
Researchers have discovered that DNA wrapped around nucleosomes exists in multiple partially open states rather than simply locked or accessible configurations.
-
NewsAAX Biotech and evitria partner on antibody development
AAX Biotech has partnered with evitria AG to expand access to its Opti-mAb® platform, enabling earlier integration of stability-enhancing technology into antibody candidate design and multispecific format development.
-
ArticleVariant or viable target? How resolving complex genomic regions is reshaping rare disease therapeutics
Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease mechanisms for targeted and effective treatments for rare diseases.
-
NewsCells use nanoparticle couriers to exchange biological information
University College Dublin researchers have discovered that cells use nanoparticle-based courier systems coated with proteins and RNA to exchange biological information. The findings detail how natural cellular gateways could be exploited to deliver therapeutic molecules to previously inaccessible locations, potentially changing the way RNA, gene and protein-based therapies work.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsLactylation emerges as key driver of lung cancer resistance
New research from Shanghai Pulmonary Hospital outlines how lactate-driven lactylation acts as a metabolic switch controlling epigenetic regulation in lung cancer. The findings reveal self-reinforcing feedback loops that sustain drug resistance and suggest novel therapeutic strategies targeting the enzymes and pathways that maintain this process.
-
WebinarManufacturing the Future: from N=1 personalised CRISPR therapy to scalable precision genomic medicine
How biotech leaders are turning one-off CRISPR breakthroughs into scalable, regulatory-ready therapies.
-
NewsFGF21 hormone targets hindbrain pathways to reverse obesity
New research reveals that FGF21, a hormone under investigation for obesity and metabolic dysfunction-associated steatohepatitis (MASH), works by signalling to the hindbrain rather than the hypothalamus. The discovery of this distinct neural circuit—which increases metabolic rate rather than simply suppressing appetite—could enable development of more precise therapies with fewer adverse effects than current FGF21 analogues.
-
ArticleFrom fragments to maps: scaling drug–target interaction data
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.